20 years is a long time to hold an ASX share, and a lot can change along the way.
But I believe some ASX shares have what it takes to keep growing and rewarding investors over that period.
With that in mind, I've picked out five shares that I would be happy to buy today and hold until 2046.
Most are businesses I have plenty of confidence in, but my final pick might come as a surprise.
Its shares have struggled this year, but I think it could prove to be a rewarding long-term investment.
Here's what's on my list and why.

Image source: Getty Images
Macquarie Group Ltd (ASX: MQG)
My first choice is Macquarie Group, which I think is one of the best financial services businesses on the ASX.
What I like about Macquarie is how it has developed multiple revenue streams across banking, asset management, commodities, and investment banking.
This gives the group exposure to different markets and opportunities around the world.
Its banking operations have continued to grow, while its global asset management business provides exposure to areas such as infrastructure, renewable energy, real estate, and private credit.
Macquarie also has considerable experience operating through difficult economic conditions.
Over a 20-year period, I would expect several recessions, market downturns, and periods of uncertainty. Having a business with a long history of managing risks and allocating capital carefully is something I value.
Of course, Macquarie's earnings can fluctuate significantly depending on market conditions and investment activity.
However, I believe its global reach, financial strength, and ability to keep developing its businesses give it an excellent chance of being considerably larger in 2046.
For these reasons, Macquarie would be an easy inclusion in my long-term portfolio.
What about the other four?
While Macquarie is a relatively straightforward choice, the remaining four offer exposure to some of the biggest growth opportunities I see over the coming decades.
They include businesses positioned to benefit from healthcare demand, Australia's growing wealth, and medical innovation.
But my final selection is perhaps the most interesting of the five. It operates in an industry where fortunes can change quickly, and its shares have fallen approximately 35% this year.
Despite that, I believe its competitive position could make it a rewarding investment for patient shareholders.
Here's why these four ASX shares would make my list along with Macquarie.
Sigma Healthcare Ltd (ASX: SIG)
Another business I would be comfortable holding for 20 years is Sigma Healthcare.
Following its merger with Chemist Warehouse, Sigma has become a major force in the Australian pharmacy industry, with a growing international presence.
I like the long-term outlook for this business because demand for medicines, healthcare products, and pharmacy services should continue to grow as populations age.
Chemist Warehouse also has a well-established brand and a retail model that has proven successful in Australia.
I think the opportunity to expand that model internationally could become an increasingly important source of growth. And we are already seeing encouraging progress, with the company's international operations growing strongly and its store network expanding.
There should also be benefits as Sigma continues integrating the two businesses, improving efficiency and expanding its range of owned and exclusive-label products.
The shares currently command a premium valuation at 36 times FY27 earnings according to CommSec, which is something investors need to consider. Nevertheless, I believe its defensive earnings, strong long-term growth potential, and market leadership justify this premium.
HUB24 Ltd (ASX: HUB)
HUB24 is another ASX share that I think could deliver excellent returns for long-term investors.
The company operates a leading investment and superannuation platform used by financial advisers to manage their clients' wealth.
Its growth opportunity is supported by Australia's expanding superannuation system and the increasing complexity of retirement planning.
As more Australians accumulate wealth and seek financial advice, I expect demand for sophisticated investment platforms to remain strong.
HUB24 has been taking advantage of this opportunity by winning business from competitors and attracting substantial inflows onto its platform.
For example, its first-quarter update for FY27 showed funds under administration had reached $168.6 billion, up 15% on the prior corresponding period.
As those assets increase, so does the revenue HUB24 can generate from administering them.
According to CommSec, HUB24 shares are trading on a PE ratio of 34 times FY28 earnings. That certainly is a premium valuation, but given its decades-long growth runway, it is a price I would be willing to pay.
Telix Pharmaceuticals Ltd (ASX: TLX)
The next ASX share I would happily hold until 2046 is Telix Pharmaceuticals.
I believe Telix has one of the most exciting long-term growth opportunities in the Australian healthcare sector.
The company specialises in radiopharmaceuticals, developing products that use radioactive substances to help diagnose and potentially treat serious diseases, including cancer.
Its commercial success with prostate cancer imaging products Illuccix and Gozellix has already demonstrated the demand for its technology.
And the opportunity extends well beyond these existing products. Telix is developing additional diagnostic products and cancer treatments, giving it several potential avenues for growth over the coming years.
The ASX announcement of the US approval of its brain cancer imaging product Pixclara in September is another encouraging development.
Looking ahead, I expect advances in medical technology and growing demand for more precise cancer diagnosis and treatment to create substantial opportunities for companies operating in this field.
There are risks to consider, particularly around clinical trials, regulatory approvals, competition, and the costs of developing new products. But with an established commercial business and an expanding pipeline, I believe Telix has the potential to become a much larger global healthcare company over the next two decades.
PLS Group Ltd (ASX: PLS)
My final ASX share is probably the one that will raise the most eyebrows.
I would be prepared to buy PLS shares today and hold them for the next 20 years.
That might sound surprising given the company's exposure to the notoriously volatile lithium market. And with its shares down approximately 35% year-to-date, investors have already had a reminder of how quickly sentiment can change.
However, I believe PLS has some important advantages that could help it prosper over the long term.
The first is its position as one of the world's leading lithium producers. Its flagship Pilgangoora operation in Western Australia is a large-scale, relatively low-cost asset with substantial resources.
In fact, the company recently increased its Pilgangoora ore reserve, which now supports more than 25 years of potential production. This gives PLS a strong starting point for a 20-year investment.
The company is also investing $1.9 billion in the P2000 project, which is expected to increase annual production capacity to approximately 2 million tonnes.
For context, this week PLS announced to the ASX record spodumene concentrate production of 267,600 tonnes in the September quarter, equivalent to just over 1 million tonnes annualised.
Beyond Australia, its acquisition of Latin Resources has given it ownership of the Colina lithium project in Brazil, creating another potential source of future production.
Of course, I would expect plenty of ups and downs over 20 years. Lithium prices will fluctuate, new supply will enter the market, and demand from electric vehicles and energy storage systems may develop unevenly.
Its expansion plans also require substantial investment, which increases the importance of careful financial management.
But I believe low operating costs, an enormous resource base, opportunities for further acquisitions, and strong cash-generating potential put PLS in a good position to navigate those challenges.
Foolish takeaway
Choosing ASX shares to hold for 20 years requires plenty of patience and a willingness to accept uncertainty.
Even outstanding businesses will encounter challenges over that period, and I would continue reviewing their progress to make sure the original investment case remains intact.
For me, these five companies offer a compelling combination of established market positions and opportunities to grow.
And while PLS might require the strongest stomach of the group, I think its long-term potential deserves serious consideration.